Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of ProKidney Corp (NASDAQ: PROK) was $2.23 for the day, down -0.45% from the previous closing price of $2.24. In other words, the price has decreased by -$0.45 from its previous closing price. On the day, 1.86 million shares were traded. PROK stock price reached its highest trading level at $2.292 during the session, while it also had its lowest trading level at $2.155.
Ratios:
Our analysis of PROK’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.32 and its Current Ratio is at 10.32.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on December 16, 2025, initiated with a Buy rating and assigned the stock a target price of $12.
On June 30, 2025, BofA Securities Downgraded its rating to Underperform which previously was Neutral but kept the price unchanged to $1.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 13 ’25 when Pereira Brian JG sold 502,136 shares for $2.37 per share. The transaction valued at 1,190,062 led to the insider holds 0 shares of the business.
Pereira Brian JG sold 255,026 shares of PROK for $694,515 on Nov 12 ’25. The Director now owns 54,333 shares after completing the transaction at $2.72 per share. On Nov 12 ’25, another insider, Brian Pereira, who serves as the Director of the company, bought 675,234 shares for $2.70 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PROK now has a Market Capitalization of 670860672 and an Enterprise Value of 1374515328. For the stock, the TTM Price-to-Sale (P/S) ratio is 906.57. Its current Enterprise Value per Revenue stands at 1847.467 whereas that against EBITDA is -8.352.
Stock Price History:
The Beta on a monthly basis for PROK is 1.82, which has changed by 0.23204422 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, PROK has reached a high of $7.13, while it has fallen to a 52-week low of $0.46. The 50-Day Moving Average of the stock is -10.89%, while the 200-Day Moving Average is calculated to be 12.13%.
Shares Statistics:
PROK traded an average of 1.66M shares per day over the past three months and 1253120 shares per day over the past ten days. A total of 135.98M shares are outstanding, with a floating share count of 105.52M. Insiders hold about 25.45% of the company’s shares, while institutions hold 28.50% stake in the company. Shares short for PROK as of 1765756800 were 13812601 with a Short Ratio of 8.34, compared to 1763078400 on 13964229. Therefore, it implies a Short% of Shares Outstanding of 13812601 and a Short% of Float of 13.420000000000002.
Earnings Estimates
The performance of ProKidney Corp (PROK) in the stock market is under the watchful eye of 6.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.16 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.41 and -$1.07 for the fiscal current year, implying an average EPS of -$0.59. EPS for the following year is -$0.64, with 6.0 analysts recommending between -$0.42 and -$1.2.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 5 analysts. It ranges from a high estimate of $250k to a low estimate of -$447k. As of. The current estimate, ProKidney Corp’s year-ago sales were $76k
